Neuroendocrine Tumor

Specifically, pituicytomas associated with pituitary hyperfunction are notably infrequent, and those linked to Cushing's disease are extremely uncommon. This case highlights the exceptional rarity of sellar collision tumors and underscores the importance of reporting such cases to improve recognition, refine diagnostic strategies, and expand current understanding of complex pituitary tumor biology.

Early disease detection, achievement of disease-free status, and favorable postoperative biochemical markers are key predictors of survival in MTC. These findings underscore the importance of timely diagnosis and comprehensive management.

She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.

P1/2, N=25, Recruiting, Teclison Ltd. | Trial completion date: Dec 2025 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Mar 2028

Quantitative digital pathology reveals distinct metabolic signatures in LNETs. MCT1 and SLC7A5 emerge as prognostic biomarkers, with MCT1 independently predicting RFS. Integrating metabolic immunophenotyping with histopathology refines risk stratification-especially for AC-and highlights potentially actionable metabolic axes for future therapeutic interventions in LNETs.

The phospho-mimetic S487D mutant remained cytoplasmic and phenocopied CTD deletion of NLS1-3 sustaining de-repression of GASTRIN . These findings showed that Ser487 phosphorylation restricts nuclear accumulation of Menin and functionally links extracellular signaling to post-translational modification of Menin that ultimately contributes to transcriptional derepression and neuroendocrine tumorigenesis.

Histopathology confirmed IL-6 expression within tumour cells. This case highlights the importance of considering cytokine-secreting paragangliomas in patients with unexplained systemic inflammation, even in the absence of catecholamine hypersecretion.

In this Review, we aim to: (1) summarise the distinct mechanisms of dysglycaemia arising from cancer and neuroendocrine tumour treatments, including targeted therapies such as PI3K-AKT-mTOR inhibitors, antibody-drug conjugates, immune checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands; (2) examine the often overlooked aspect of the secondary cause of diabetes as an early manifestation of cancer; and (3) highlight research gaps and encourage a collaborative care approach to manage the rising rate of dysglycaemia as a result of cancer and its evolving treatments. To address the first two objectives, we incorporate relevant case vignettes to contextualise the discussions.

P=N/A, N=50, Recruiting, Institute for Clinical and Experimental Medicine

P3, N=240, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2030 --> Dec 2028

P=N/A, N=500, Active, not recruiting, West China Hospital